Low-dose aspirin should be used in colorectal cancer prevention studies, researchers say.
This article was originally published in The Tan Sheet
Executive Summary
LOW-DOSE ASPIRIN FOR COLORECTAL CANCER STUDIES SUGGESTED based on the results of a 66-patient, 14-day study measuring the effect of aspirin at 40.5 mg, 81 mg, 162 mg, 324 mg and 648 mg daily on prostaglandins E2 and F2alpha. The short-term study by Mack Ruffin et al., University of Michigan, published in the Aug. 6 Journal of the National Cancer Institute, was conducted to determine the lowest dose of aspirin that could significantly reduce the level of colorectal prostaglandins as a baseline for future studies seeking to find new chemopreventive agents for colorectal cancers. High levels of prostaglandins have been found in colon cancer tissues.